TP53: A key gene in human cancer

Biochimie

Volumn 84, Issue 1, 2002, Pages 83-93

  Guimaraes, D P ^a   Hainaut, P ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

DNA damage; Hypoxia; Multistep carcinogenesis; Mutation; P14arf; TP53

Indexed keywords

CARCINOGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A; CYCLINE; CYCLOOXYGENASE 2; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; CLONAL VARIATION; GENE MUTATION; GENOTOXICITY; GROWTH INHIBITION; HUMAN; MOLECULAR DYNAMICS; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 0036251645     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(01)01356-6     Document Type: Article

References (97)

1. The hallmarks of cancer
2. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer
3. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions
4. p63 and p73: Old members of a new family
5. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
6. p63 is a p53 homologue required for limb and epidermal morphogenesis
7. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours
8. Tumors associated with p53 germline mutations: A synopsis of 91 families
9. p53 and human cancer: The first ten thousand mutations
10. Genotoxic and non-genotoxic pathways of p53 induction
11. Surfing the p53 network
12. Twenty years of p53 research: Structural and functional aspects of the p53 protein
13. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
14. Redox signalling and transition metals in the control of the p53 pathway
15. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes
16. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke
17. Hepatocellular carcinoma: From gene to public health
18. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent
19. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation
20. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
21. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
22. The value of rapid functional assays of germline p53 status in LFS and LFL families
23. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
24. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene
25. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis
26. Two polymorphic variants of wild-type p53 differ biochemically and biologically
27. The p53 codon 72 polymorphism and lung cancer risk
28. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients
29. p53 codon 72 polymorphism in Taiwanese lung cancer patients: Association with lung cancer susceptibility and prognosis
30. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
31. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection
32. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China
33. p53 codon 72 polymorphism and risk of cervical cancer in UK
34. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix
35. The MDM2 gene amplification database
36. Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells
37. Functions of the MDM2 oncoprotein
38. Mdm2: Keeping p53 under control
39. Signaling to p53: Breaking the posttranslational modification code
40. Post-translational modifications and activation of p53 by genotoxic stresses
41. The complexity of p53 modulation: Emerging patterns from divergent signals
42. Cancer. p53, guardian of the genome
43. The INK4a/ARF tumor suppressor: One gene - two products - two pathways
44. Complex structure and regulation of the P16 (MTS1) locus
45. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2
46. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
47. Activation of p53 by oncogenes
48. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
49. MEKK1/JNK signaling stabilizes and activates p53
50. JNK targets p53 ubiquitination and degradation in non-stressed cells
51. JunNH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress
52. A genetic model for colorectal tumorigenesis
53. The use of biomarkers to study pathogenesis and mechanisms of cancer: Oesophagus and skin cancer as models
54. Evolution of neoplastic cell lineages in Barrett oesophagus
55. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes
56. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
57. p53: Oncogene or anti-oncogene?
58. p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect
59. Gain-of-function mutations in the tumor suppressor gene p53
60. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants
61. Physical and functional interaction between p53 mutants and different isoforms of p73
62. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay
63. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
64. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
65. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients
66. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia
67. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer
68. Cancer therapy and p53
69. The results of colorectal cancer treatment by p53 status: Treatment-specific overview
70. TP53 gene and p53 proteins as targets in cancer management and therapy
71. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
72. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
73. Pharmacological rescue of mutant p53 conformation and function
74. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
75. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway
76. Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner
77. GADD45 induction of a G2/M cell cycle checkpoint
78. Association of the cyclin-dependent kinases and -3 sigma negatively regulates cell cycle progression
79. ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter
80. A role of cyclin G in the process of apoptosis
81. Regulation of p53 downstream genes
82. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism
83. Negative regulation of bcl-2 expression by p53 in hematopoietic cells
84. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
85. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
86. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
87. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
88. Is, PUMAa Novel Proapoptotic Gene Induced by p53
89. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway
90. Interaction of p53 with the human Rad51 protein
91. Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53
92. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations
93. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
94. Inhibition of cyclooxygenase-2 gene expression by p53
95. HSP70 binding sites in the tumor suppressor protein p53
96. Wild-type p53 inhibits protein kinase CK2 activity
97. Mdm2 association with p53 targets its ubiquitination